Search Within

Maria Lia Palomba

Formats
  1. Meeting Abstract (289)
  2. Journal Article (131)
  3. Research Letter (10)
  4. Review (8)
  5. Correspondence (4)
  6. Editorial (3)
  7. Book Section (1)
  8. Conference Paper (1)
  9. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (448)
  2. Department of Medicine (448)
  3. Hematologic Malignancies, Division of (448)
  4. Lymphoma (448)
  5. Hematology-Oncology Fellows (228)
  6. Survivorship Research (209)

More Groups

People
  1. Andrew Zelenetz (143)
  2. Ariela Noy (132)
  3. Paul Hamlin (126)
  4. Gilles Salles (114)
  5. Steven Horwitz (112)
  6. Gunjan Shah (111)

More People

Years
  1. 2025 (19)
  2. 2024 (58)
  3. 2023 (69)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (43)

More Years

Publications
  1. Blood (187)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (30)
  4. Blood Advances (19)
  5. Blood Cancer Journal (15)
  6. British Journal of Haematology (14)

More Publications

Publishers
  1. American Society of Hematology (207)
  2. Elsevier Inc. (45)
  3. American Society of Clinical Oncology (38)
  4. Nature Publishing Group (33)
  5. Wiley Blackwell (31)
  6. John Wiley & Sons (14)

More Publishers

Results (448)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in TRANSCEND NHL 001
    Meeting Abstract

    Palomba, M. L.; Gordon, L. I.; Siddiqi, T.; Abramson, J. S.; Kamdar, M.; Lunning, M. A.; Maloney, D. G.; Andreadis, C.; Arnason, J. E.; Ghosh, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Clinical impact of bridging therapy prior to commercial chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory lymphomas
    Meeting Abstract

    Imber, B. S.; Perales, M. A.; Flynn, J.; Ruiz, J. D.; Devlin, S.; Alarcon Tomas, A.; Hajj, C.; Batlevi, C. L.; Dahi, P. B.; Lin, R. J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • CD5-positive marginal zone lymphoma: Clinical characteristics of the MSKCC Cohort, and comparison with the CD5-negative population
    Meeting Abstract

    Ghione, P.; Bantilan, K. S.; Joffe, E.; Lia Palomba, M.; Noy, A.; Matasar, M. J.; Caron, P.; Hamilton, A.; Hamlin, P. A.; Kumar, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Five-year follow-up of ibrutinib plus rituximab vs placebo plus rituximab for Waldenström's macroglobulinemia: Final analysis from the randomized phase 3 iNNOVATE™ study
    Meeting Abstract

    Buske, C.; Tedeschi, A.; Trotman, J.; García-Sanz, R.; MacDonald, D.; Leblond, V.; Mahé, B.; Herbaux, C.; Matous, J. V.; Tam, C. S.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice
    Meeting Abstract

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Abramson, J. S.; Siddiqi, T.; Gordon, L. I.; Lunning, M. A.; Wang, M.; Arnason, J. E.; Mehta, A. N.; Purev, E.; Maloney, D. G.; Andreadis, C.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Consensus statement on the management of Waldenström macroglobulinemia patients during the COVID-19 pandemic
    Guidelines

    Talaulikar, D.; Advani, R. H.; Branagan, A. R.; Buske, C.; Dimopoulos, M. A.; D'Sa, S.; Kersten, M. J.; Leblond, V.; Minnema, M. C.; Owen, R. G.; more...
    HemaSphere (2020)

    Fulltext@MSK | Save